$TYME News Article - TYME Presented Updated Data at ESMO 2019 from SM-88 Phase II Prostate Cancer Study Demonstrating Encouraging Clinical Benefit in Patients with Recurrent Prostate Cancer https://marketwirenews.com/news-releases/tyme...60139.html
(0)
(0)
Tyme Technologies Inc. (TYME) Stock Research Links